LJPC - La Jolla Pharmaceutical Company
| Previous Close | 22.71 |
| Open | 23.20 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 22.87 - 24.01 |
| 52 Week Range | 20.25 - 41.36 |
| Volume | 455,045 |
| Avg. Volume | 455,685 |
| Market Cap | 624.306M |
| Beta | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.21 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.00 |
- GlobeNewswire•6 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasizes Economic Growth
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion ...
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of LJPC earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 La Jolla Pharmaceutical Co Earnings Call
- Motley Fool•13 days ago
Why La Jolla Pharmaceutical Is Tumbling Today
Shares drop off after the company reports second-quarter results that left investors wanting more.
- Zacks•13 days ago
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
La Jolla Pharmaceutical: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•13 days ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
SAN DIEGO, Aug. 08, 2018-- La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering ...
- ACCESSWIRE•13 days ago
La Jolla Pharmaceutical Company to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
- GlobeNewswire•19 days ago
La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for GIAPREZATM (angiotensin II) Injection for Intravenous Infusion. GIAPREZA is indicated to increase blood pressure in adults with septic or other distributive shock. The CMS NTAP program provides additional reimbursement to hospitals beyond the Medicare Severity Diagnosis-Related Group (MS-DRG) reimbursement for specific products that meet strict criteria for the treatment of Medicare patients.
- GlobeNewswire•20 days ago
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
SAN DIEGO, Aug. 01, 2018-- La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering ...
- ACCESSWIRE•last month
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Marketing Authorisation Application (MAA) for GIAPREZA (angiotensin II) Injection for Intravenous Infusion was validated by the European Medicines Agency (EMA). Validation of the MAA confirms that the submission is complete and starts the EMA’s centralized review process. La Jolla submitted the GIAPREZA MAA for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy.
- InvestorPlace•2 months ago
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
- ACCESSWIRE•2 months ago
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
- ACCESSWIRE•3 months ago
Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
- Simply Wall St.•3 months ago
What Should We Expect From La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Earnings In The Next Couple Of Years?
The latest earnings release La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) announced in December 2017 showed company earnings became less negative compared to the previous year’s level as a result of recentRead More...
- Associated Press•3 months ago
La Jolla Pharmaceutical: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of $2.22. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- PR Newswire•4 months ago
CalciMedica Names Two Senior Executives to its Board of Directors
LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences. The two new Board members bring extensive clinical development and financing/transaction experience, respectively, to CalciMedica as it advances its novel acute pancreatitis agent, CM4620, through clinical development.
